Fecal Hemoglobin Concentrations Varies with Gender and Age
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
|
Estimation of fecal hemoglobin concentration by fecal immunochemical tests (FIT) are becoming widely used in colorectal cancer screening.
Risk stratification is based on the concentration of the hemoglobin in the stool specimens and this helps clinicians make the subsequent decisions for diagnosis and treatment of colorectal neoplasia.
Scientists at the University of Dundee (UK) carried out a large observational study by making a single estimate of fecal hemoglobin concentration using quantitative automated immunoturbidimetry. From July 1, 2010, to January 12, 2011, all eligible men and women aged between 50 and 74 years resident in two of the 14 National Health Service Boards in Scotland were invited to participate. To investigate potential reference values, those who returned a testable fecal sample were defined as the reference population. No exclusion criteria were applied.
The reference sample group comprised of 38,720 in total, including 18,058 men (46.6 %) and 20,662 women (53.4 %) who returned a testable sample. The potential upper reference limits, were 519 ng hemoglobin/mL (90% Confidence Interval (CI): 468-575) for men and 283 ng hemoglobin/mL (90% CI: 257-316) for women. The concentration of hemoglobin increased with age in both genders. The decision limits have advantages over the reference intervals. At any cut-off concentration, more men are declared positive than women and more older people are declared positive than younger people. Future risk of neoplasia is higher in men than in women and in older people.
The authors concluded that that the truly healthy individual has no detectable fecal hemoglobin by conventional quantitative methodology and that any hemoglobin present is unusual. Fecal hemoglobin concentrations vary with gender and age and should be included in individual risk assessment scores. They suggest that more tailored strategies are needed in colorectal cancer screening programs. The study was published on May 25, 2012, in the journal Clinical Chemistry and Laboratory Medicine.
Related Links:
University of Dundee
Risk stratification is based on the concentration of the hemoglobin in the stool specimens and this helps clinicians make the subsequent decisions for diagnosis and treatment of colorectal neoplasia.
Scientists at the University of Dundee (UK) carried out a large observational study by making a single estimate of fecal hemoglobin concentration using quantitative automated immunoturbidimetry. From July 1, 2010, to January 12, 2011, all eligible men and women aged between 50 and 74 years resident in two of the 14 National Health Service Boards in Scotland were invited to participate. To investigate potential reference values, those who returned a testable fecal sample were defined as the reference population. No exclusion criteria were applied.
The reference sample group comprised of 38,720 in total, including 18,058 men (46.6 %) and 20,662 women (53.4 %) who returned a testable sample. The potential upper reference limits, were 519 ng hemoglobin/mL (90% Confidence Interval (CI): 468-575) for men and 283 ng hemoglobin/mL (90% CI: 257-316) for women. The concentration of hemoglobin increased with age in both genders. The decision limits have advantages over the reference intervals. At any cut-off concentration, more men are declared positive than women and more older people are declared positive than younger people. Future risk of neoplasia is higher in men than in women and in older people.
The authors concluded that that the truly healthy individual has no detectable fecal hemoglobin by conventional quantitative methodology and that any hemoglobin present is unusual. Fecal hemoglobin concentrations vary with gender and age and should be included in individual risk assessment scores. They suggest that more tailored strategies are needed in colorectal cancer screening programs. The study was published on May 25, 2012, in the journal Clinical Chemistry and Laboratory Medicine.
Related Links:
University of Dundee
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Multi-Chamber Washer-Disinfector
WD 390
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Latest Clinical Chem. News
- Saliva-Based Test Detects Biochemical Signs of Sleep Loss
- Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
- Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
- Urine-Based Test Shows Promise for Autism Screening in Children
- Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s
- Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis
- Urine-Based Alzheimer’s Test Receives FDA Breakthrough Device Designation
- Fluid Biomarker Improves Diagnosis and Monitoring of Primary CNS Lymphoma
- New CA19-9 Cutoff Value Helps Identify High-Risk Pancreatic Cancer Patients
- Blood-Based Biomarkers Show Promise for Psychosis Risk Prediction
- International Experts Recommend Ending Routine 'Corrected' Calcium Reporting
- Long-Term Data Show PSA Screening Modestly Reduces Prostate Cancer Deaths
- Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
- FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Channels
Molecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Hematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read more
Immunology
view channel
Aptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Microbiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read more
Pathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
Technology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read more
Industry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more
